Ribeiro da Cunha Maria, Marques Tiago
Department of Infectious Diseases, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
ACG Case Rep J. 2021 Nov 19;8(11):e00674. doi: 10.14309/crj.0000000000000674. eCollection 2021 Nov.
Hepatitis E virus (HEV) is a mostly enterically transmitted agent of viral, usually acute hepatitis. In recent years, however, it has been proven to establish chronicity in immunosuppressed patients. We report the first case of HEV infection in a patient with myelofibrosis under ruxolitinib, a tyrosine kinase inhibitor. Although this patient was able to mount a humoral response with specific immunoglobulin G, viral replication could not be controlled until ruxolitinib suspension. After normalization of liver enzymes and clearance of HEV, ruxolitinib was reintroduced with no disease relapse, suggesting spontaneous eradication of the virus.
戊型肝炎病毒（HEV）是一种主要经肠道传播的病毒，通常引起急性肝炎。然而，近年来已证实它可在免疫抑制患者中导致慢性感染。我们报告了首例在接受酪氨酸激酶抑制剂鲁索替尼治疗的骨髓纤维化患者中发生HEV感染的病例。尽管该患者能够产生具有特异性免疫球蛋白G的体液反应，但在停用鲁索替尼之前病毒复制无法得到控制。在肝酶恢复正常且HEV清除后，重新使用鲁索替尼，未出现疾病复发，提示病毒已自发清除。
